Prof. Dr. Christoph Mundhenke

Professur für Gynäkologie und Geburtsmedizin am Medizincampus Oberfranken

Eribulin (Halaven) in advanced mammary carcinoma Eribulin beim fortgeschrittenen mammakarzinom: Handelsname: Halaven (D, A, CH) (2012) Wenners A, Heilmann T, Mundhenke C Journal article Congenital retroperitoneal vascular anomalies: Impact on pelvic surgery (2011) Strauss A, Kuemper C, Mundhenke C, Schaefer F, Jonat W, Hilpert F Journal article Breast ultrasound elastography-results of 193 breast lesions in a prospective study with histopathologic correlation (2011) Schaefer FKW, Heer I, Schaefer PJ, Mundhenke C, Osterholz S, Order BM, Hofheinz N, et al. Journal article Epidemiology of vulvar and vaginal cancer in Germany (2011) Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D Journal article Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer (2011) Von Minckwitz G, Schweller K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, et al. Journal article In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells (2010) Weigel MT, Dahmke L, Schem C, Bauerschlag DO, Weber K, Niehoff P, Bauer M, et al. Journal article Therapeutic recommendations for mammary carcinoma Therapieempfehlungen bei mammakarzinom (2010) Mundhenke C Journal article Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer (2010) Bauerschlag DO, Habermann M, Weimer J, Meinhold-Heerlein I, Hilpert F, Weigel M, Bauer M, et al. Journal article Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial (2010) Witzel I, Loibl S, Von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, et al. Journal article Dexrazoxane (Savene) is the standard therapy for anthracycline extravasation Dexrazoxan (Savene) als Standard in der Therapie von Anthrazyklinparavasaten (2010) Mundhenke C Journal article